How many drugs treat Behcet's disease?

Drug Landscape tracks 9 marketed treatments for Behcet's disease (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/behcet-s-disease.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Behcet's disease — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Behcet's disease (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Behcet's disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Abrilada	Adalimumab-Afzb	AbbVie	TNF blocker	Tumor necrosis factor-alpha (TNF-alpha)	2002-01-01
Humira	ADALIMUMAB	AbbVie	TNF blocker	Tumor Necrosis Factor-alpha (TNF-alpha)	2002-01-01
Remicade	Infliximab-Dyyb	Johnson & Johnson	TNF blocker	Tumor Necrosis Factor alpha (TNFα)	1998-01-01
Remicade	INFLIXIMAB	Johnson & Johnson	Tumor Necrosis Factor Blocker [EPC]	Tumor necrosis factor	1998-01-01
Imuran	AZATHIOPRINE	Legacy Pharma	Purine Antimetabolite [EPC]	ATP-binding cassette sub-family G member 2	1968-01-01
Remicade	Remicade	Shanghai Biomabs Pharmaceutical Co., Ltd.		Tumor necrosis factor
CYLTEZO	ADALIMUMAB-ADBM	BOEHRINGER INGELHEIM		Tumor necrosis factor
IXIFI	INFLIXIMAB-QBTX	PFIZER INC		Tumor necrosis factor
Humira	Humira	Sohag University		Tumor necrosis factor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Johnson & Johnson · 3 drugs in Behcet's disease
AbbVie · 2 drugs in Behcet's disease
PFIZER INC · 1 drug in Behcet's disease
Shanghai Biomabs Pharmaceutical Co., Ltd. · 1 drug in Behcet's disease
Sohag University · 1 drug in Behcet's disease
Legacy Pharma · 1 drug in Behcet's disease
BOEHRINGER INGELHEIM · 1 drug in Behcet's disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Behcet's disease:

Cite this brief

Drug Landscape (2026). Behcet's disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/behcet-s-disease. Accessed 2026-06-10.

Behcet's disease full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing